Keros Therapeutics (NASDAQ:KROS) Director Acquires $10,190.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Jean Jacques Bienaime bought 1,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was acquired at an average cost of $10.19 per share, for a total transaction of $10,190.00. Following the purchase, the director owned 17,592 shares in the company, valued at approximately $179,262.48. This trade represents a 6.03% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, April 15th, Jean Jacques Bienaime bought 1,000 shares of Keros Therapeutics stock. The stock was acquired at an average cost of $11.70 per share, for a total transaction of $11,700.00.

Keros Therapeutics Stock Up 3.8%

Shares of KROS stock traded up $0.38 during mid-day trading on Wednesday, reaching $10.41. The company’s stock had a trading volume of 241,766 shares, compared to its average volume of 369,511. The company’s 50 day simple moving average is $11.16 and its 200-day simple moving average is $14.80. Keros Therapeutics, Inc. has a 12-month low of $9.69 and a 12-month high of $22.55. The firm has a market capitalization of $206.03 million, a PE ratio of -3.46 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The business had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. As a group, research analysts anticipate that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its stake in Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares during the period. UBS Group AG increased its stake in Keros Therapeutics by 1.1% during the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after buying an additional 1,091 shares during the period. Strs Ohio increased its stake in Keros Therapeutics by 3.9% during the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after buying an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares during the period. Finally, Financial Management Professionals Inc. purchased a new stake in Keros Therapeutics during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KROS. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Finally, Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.